Abstract

Secretagogin (SCGN) has recently been identified to play a crucial role in cell apoptosis, receptor signaling and differentiation. However, its clinical significance and functional roles in SCLC chemoresistance remain unknown. Here we examined the expression of SCGN in clinical samples from SCLC patients and evaluated its relation with clinical prognosis. Then up and down-regulation of SCGN were carried out in SCLC cell lines to assess its influence on chemoresistance. Furthermore, luciferase reporter assay was used to evaluate whether SCGN is a novel direct target of miR-494. Our results revealed that elevated expression of SCGN was correlated with the poorer prognosis of SCLC patients and the more significant correlation with chemosensitivity. We also found that knockdown of SCGN expression in H69AR and H446AR cells increased chemosensitivity via increasing cell apoptosis and cell cycle arrest of G0/G1 phase, while over-expression of SCGN reduced chemosensitivity in sensitive H69 and H446 cells. SCGN as a novel target of miR-494 by luciferase reporter assay, up-regulation of miR-494 can sensitize H69AR cells to chemotherapeutic drugs. These results suggest SCGN is involved in the chemoresistance of SCLC under the regulation of miR-494 and may be a potential biomarker for predicting therapeutic response in treatment SCLC.

Highlights

  • Lung cancer is one of the leading malignant tumors in the world

  • Lower expression of SCGN was shown in limited diseaseSCLC (LD-Small cell lung cancer (SCLC)) than that in extensive disease-SCLC (ED-SCLC) (P=0.000)

  • We reported the expression of SCGN and miR-494 in SCLC and its association with chemoresistance and clinical prognosis

Read more

Summary

Introduction

Lung cancer is one of the leading malignant tumors in the world. Small cell lung cancer (SCLC) accounts for approximately 15% of all lung cancers at present. Chemoresistance has become one of the major problems in the chemotherapy, it is an important clinical issue to cause poor prognosis of SCLC.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call